Form 4: Prothena Corp Public Ltd Co: Chief Accounting Officer Karin L. Walker Reports Stock Option Grant
SEC Form 4 Filing
Karin L. Walker, Chief Accounting Officer of Prothena Corp Public Ltd Co, reports the acquisition of stock options for 54,000 ordinary shares.
Summary
- On February 27, 2024, Karin L. Walker, the Chief Accounting Officer of Prothena Corp Public Ltd Co, was granted stock options for 54,000 ordinary shares.
- The exercise price of the options is $30.3.
- The options vest over a period of four years, starting with 25% vesting on February 27, 2025, and the remainder vesting in equal monthly installments thereafter, contingent upon continued employment.
- The options expire on February 27, 2034.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive. The granting of stock options is a standard practice and generally viewed as a positive incentive for management.
Positives
- The grant of stock options to the Chief Accounting Officer aligns her interests with those of the shareholders.
- The vesting schedule incentivizes continued employment and contribution to the company's success.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders and incentivizing long-term value creation.
Comparison to Industry Standards
- Stock option grants are a standard component of compensation packages for executives in publicly traded companies, particularly in the biotech sector.
- The vesting schedule of 25% after one year followed by monthly installments is a typical arrangement to encourage long-term commitment.
- Comparing the size of the grant (54,000 shares) to similar companies and executive roles would require further benchmarking data.
Stakeholder Impact
- The stock option grant could potentially increase shareholder value if the executive's performance leads to an increase in the company's stock price.
- The vesting schedule incentivizes the executive to remain with the company, providing stability and expertise.
Key Dates
| Date | Description |
|---|---|
| 02/27/2024 | Date of the stock option grant. |
| 02/27/2025 | Date when 25% of the stock options vest. |
| 02/27/2034 | Expiration date of the stock options. |
| 02/29/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.